| |
RA+aTNF
|
RA+MTX
|
RA
|
Healthy Controls
|
|---|
|
N
|
61
|
70
|
33
|
97
|
|
Age, mean +/- SD years
|
55.4 +/- 12.3
|
58.4 +/-12.2
|
57.1 +/-13.8
|
39.8 +/- 13.6
|
|
% female
|
82%
|
77%
|
64%
|
63%
|
|
Disease duration < 1 year
|
5%
|
17%
|
45%
|
NA
|
|
Disease duration > 3 years
|
93%
|
60%
|
47%
|
NA
|
|
Adalimumab n (%)
|
9 (15)
|
NA
|
NA
|
NA
|
|
Infliximab n (%)
|
17 (28)
|
NA
|
NA
|
NA
|
|
Etanercept n (%)
|
35 (57)
|
NA
|
NA
|
NA
|
|
MTX n (%)
|
49 (80)
|
70 (100)
|
0 (0)
|
NA
|
|
MTX, dose +/- SD mg/wk
|
15.2 +/- 4.3
|
16.5 +/- 4.0
|
NA
|
NA
|
|
corticosteroid n (%)
|
18 (29.5)
|
26 (37.1)
|
10 (30.3)
|
NA
|
|
corticosteroid, dose +/- SD mg/d
|
5.5 +/- 3.5
|
4.9 +/- 2.0
|
10.3 +/-6.1
|
NA
|
|
ESR mean (range)
|
21 (4-70)
|
22 (2-83)
|
20 (2-74)
|
NA
|
|
HAQ mean (range)
|
0.71 (0.00-2.22)
|
0.73 (0.00-2.75)
|
0.46 (0.00-1.63)
|
NA
|
|
VAS mean (range) cm
|
2.8 (0.0-9.8)
|
3.3 (0.0-7.5)
|
2.8 (0.0-7.1)
|
NA
|
|
Morning stiffness mean (range) min
|
81 (0-780)
|
104 (0-1440)
|
59 (0-180)
|
NA
|
|
Race non Caucasian n (%)
|
8 (13)
|
6 (9)
|
2 (6)
|
12 (12)
|
- ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; NA, not applicable; SD, standard deviation; VAS, visual analogue score.
